{"id":781679,"date":"2023-09-01T17:05:14","date_gmt":"2023-09-01T21:05:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/"},"modified":"2023-09-01T17:05:14","modified_gmt":"2023-09-01T21:05:14","slug":"g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/","title":{"rendered":"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">RESEARCH TRIANGLE PARK, N.C., Sept.  01, 2023  (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FL89uSsRC8BvgV7MjXn4AeiJ9_csBF3vlyO1m3XmHprBWNIxVy7rVeS_IN6DCcLprgq-e8YCGlKVY77Y7LNZJw==\" rel=\"nofollow noopener\" target=\"_blank\">GTHX<\/a>), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1\u2019s common stock and 3,300 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the \u201cAmended and Restated 2021 Plan\u201d). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"left\">The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual\u2019s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.<\/p>\n<p align=\"left\">The stock options are exercisable at a price of $1.70 per share, the closing price of G1\u2019s common stock on September 1, 2023, the grant date. The stock options have up to a ten-year term and vest over four years, with 25% of the award vesting on the first anniversary of the employee\u2019s employment, and as to an additional 1\/48th of the shares monthly thereafter, subject to continued service through the applicable vesting dates (subject to the terms and conditions of the stock option agreement covering the grant). The RSUs have a four-year term, with 25% of the award vesting on the first anniversary of the grant date, and the remainder vesting 12.5% semi-annually over the remaining three years, subject to continued service through the applicable vesting dates (subject to the terms and conditions of the RSU agreement covering the grant). The stock options and RSUs are subject to the terms and conditions of the Amended and Restated 2021 Plan.<\/p>\n<p align=\"left\">\n        <strong>About G1 Therapeutics<\/strong><br \/>\n        <br \/>G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company\u2019s first commercial product, COSELA\u00ae (trilaciclib). G1 has a deep clinical pipeline and is executing a development plan evaluating trilaciclib in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RBgjbA41rhdZ52cdZ4KUUv5E6Jr7ZovI3zy-fMKtCxiQ24UJTwhIrFkiFuCQGg9WYe1kAg_sQbBf9Guvk2RpUaWaEhzfxQCJo40SmRVS1TA=\" rel=\"nofollow noopener\" target=\"_blank\">www.g1therapeutics.com<\/a> and follow us on Twitter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yHWJ_a5OkDGtb8ksRKwlv5LpgKbIXQYNk3-KVnWuk4W-1OA1fEQybTPQb59dekps4lmim_itkkUHtBXNxLfY2e2nvY7gCrNDVVO5ezMGy0Y=\" rel=\"nofollow noopener\" target=\"_blank\">@G1Therapeutics<\/a>.<\/p>\n<p align=\"left\">G1 Therapeutics\u00ae and the G1 Therapeutics logo and COSELA\u00ae and the COSELA logo are trademarks of G1 Therapeutics, Inc.<\/p>\n<p align=\"left\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p align=\"left\">Will Roberts<br \/>G1 Therapeutics, Inc.<br \/>Communications Officer<br \/>Vice President, Investor Relations and Corporate Communications<br \/>(919) 907-1944 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LzIH75Zm8t5oelr2ikPmSt79ILgstRk3dPLAD6VvQQ94dTjYHXCMk7SJBJqXc7h_DcgUkoq1G-Eve7V83nVY_Ljzs2g_WC5kIjQSA_PvUne6T5RI6gtQDlxljewYJmH7\" rel=\"nofollow noopener\" target=\"_blank\">wroberts@g1therapeutics.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Yjc3YmZkZGYtNGFkYS00ZGFhLTlhNjctMTc1OGZjYjFmZWYyLTEwNDA2Nzg=\/tiny\/G1-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1\u2019s common stock and 3,300 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the \u201cAmended and Restated 2021 Plan\u201d). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4). The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781679","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1\u2019s common stock and 3,300 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the \u201cAmended and Restated 2021 Plan\u201d). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4). The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of &hellip; Continue reading &quot;G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-01T21:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-09-01T21:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/\"},\"wordCount\":431,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/\",\"name\":\"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=\",\"datePublished\":\"2023-09-01T21:05:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/","og_locale":"en_US","og_type":"article","og_title":"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) &#8212; G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1\u2019s common stock and 3,300 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the \u201cAmended and Restated 2021 Plan\u201d). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4). The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of &hellip; Continue reading \"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-01T21:05:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-09-01T21:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/"},"wordCount":431,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/","name":"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=","datePublished":"2023-09-01T21:05:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzOCM1NzkzNTY2IzIwMjkxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/g1-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781679"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781679\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}